Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-12
2005-04-12
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S302000, C514S266400, C514S258100, C514S256000, C514S255050, C544S277000, C544S284000, C544S127000, C544S335000, C544S405000, C546S116000
Reexamination Certificate
active
06878705
ABSTRACT:
The invention provides a compound of formula I:wherein G, R2, R3, and R4have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.
REFERENCES:
patent: 4125611 (1978-11-01), Yamade et al.
patent: 4145418 (1979-03-01), Kuwada et al.
patent: 4767766 (1988-08-01), Baker et al.
patent: 4877793 (1989-10-01), Davies
patent: 4959363 (1990-09-01), Wentland
patent: 5155115 (1992-10-01), Suzuki et al.
patent: 5219864 (1993-06-01), Suzuki et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5593943 (1997-01-01), Nuebling et al.
patent: 5817819 (1998-10-01), Furuya et al.
patent: 6239142 (2001-05-01), Schnute et al.
patent: 6620810 (2003-09-01), Thorarensen
patent: 4227747 (1994-02-01), None
patent: 0046990 (1982-03-01), None
patent: 0269295 (1988-06-01), None
patent: 0443568 (1991-08-01), None
patent: 505058 (1992-09-01), None
patent: 0560348 (1993-09-01), None
patent: 1062840 (1967-03-01), None
patent: 2289276 (1995-11-01), None
patent: 46-032198 (1970-09-01), None
patent: 57116077 (1982-07-01), None
patent: 57142985 (1982-09-01), None
patent: 07076586 (1995-03-01), None
patent: 8143573 (1996-06-01), None
patent: 08301849 (1996-11-01), None
patent: 9208496 (1997-08-01), None
patent: WO-9203427 (1992-03-01), None
patent: WO-9528405 (1995-10-01), None
patent: WO-9618616 (1996-06-01), None
patent: WO-9618617 (1996-06-01), None
patent: WO-9740846 (1997-11-01), None
patent: WO-9811073 (1998-03-01), None
patent: WO-9932450 (1999-07-01), None
patent: WO-9962908 (1999-12-01), None
patent: WO-0007595 (2000-02-01), None
patent: WO-0040561 (2000-07-01), None
patent: WO-0040563 (2000-07-01), None
patent: WO-0053610 (2000-09-01), None
patent: WO-0076990 (2000-12-01), None
patent: WO-0137824 (2001-05-01), None
patent: WO-0158898 (2001-08-01), None
patent: WO-03020729 (2003-03-01), None
The Merck Manual. Eleventh Edition (1966), pp. 212-213.*
Blaskiewicz, P., et al., “Thienopyridinonecarboxylic Acid Derivatives”,Chemical Abstracts, Abstract of German Patent No. 2,447,477, Abstract No. 85:46627 (1976), 1 p.
El-Abadelah, Mustafa M., et al., “Synthesis and Chiroptical Properties of Some N-(2-Chloro-7-cyclopropyl-4,7-dihydro-4-oxo-thieno[2,3-b]pyridine-5-carbonyl) L-α-Amino Esters”,Z. Naturforsch. (1977), pp. 419-426.
Elliott, Richard L., et al., “The Preparation of 2-(Heterocyclyl)thieno[3,2-b]pyridine Derivatives”,Tetrahedron,vol. 43 (1987), pp. 3295-3302.
Goerlitzer, K., et al., “Gyrase inhibitors; Part 3.: Synthesis and reactions of ethyl 1,4-dihydro-4-oxo[1]benzothieno[3,2-b]pyridine-3-carboxylate”,Pharmazie,vol. 55 (2000), pp. 595-600.
Nishikawa, Yoshinori, et al., “Synthesis and Antiallergic Activity of N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3-carboxamides”,Chem. Pharm. Bull.,vol. 37 (1989), pp. 1256-1259.
Patani, G. A., et al., “Bioisosterism: A Rational Approach in Drug Design”,Chemical Reviews, 96(8) (1996), pp. 3147-3176.
Thornber, C. W., “Isosterism and Molecular Modification in Drug Design”,Chemical Society Reviews,8(4) (1979), pp. 563-580.
Database Crossfire Beilstein, vol. 26, No. 1,Beilstein Institut zur Foerderung der chemischen Wissenschaften,Frankfurt am Main, DE Datebase Accession No. 4321837, (1991), 3-11.
Database Crossfire Beilstein, vol. 21,Beilstein Institut zur Foerderung der chemischen Wissenschaften, Frankfurt am Main, DE Datebase Accession No. 4381517, (1984), 785-790.
Vaillancourt, V. A., et al., “Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase”,Bioorganic&Medicinal Chemistry Letters, vol. 10, No. 18,(Sep. 2000), 2079-2081.
Cudahy Michele M.
Herrinton Paul Matthew
Nair Sajiv K.
Perrault William R.
Schnute Mark E.
Huang Evelyn Mei
Pfizer
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3413581